Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 10;28(9):1841–1853. doi: 10.1158/1078-0432.CCR-21-1242

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 5. Longitudinal cfDNA monitoring in patients with cancer who received treatments. The lines show the tumor fraction in cfDNA during treatment. A, Tumor fraction in plasma samples of 8 patients with NSCLC who received anti-PD-1 immunotherapy. B, Tumor fraction in serum samples of 4 patients with ovarian cancer. C, Tumor fraction in plasma samples of 12 patients with prostate cancer. — Longitudinal cfDNA monitoring in patients with cancer who received treatments. The lines show the tumor fraction in cfDNA during treatment. A, Tumor fraction in plasma samples of 8 patients with NSCLC who received anti-PD-1 immunotherapy. B, Tumor fraction in serum samples of 4 patients with ovarian cancer. C, Tumor fraction in plasma samples of 12 patients with prostate cancer.